martes, 13 de abril de 2021

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine

No hay comentarios:

Publicar un comentario